文献速递其他结缔组织病

Teclistamab治疗难治性系统性硬化症:快速临床应答与深部组织B细胞清除

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.
PubMed 文献 · Ann Rheum Dis · 2026-06-19

治疗实现骨髓和皮肤中B细胞与浆细胞的近乎完全清除,抗拓扑异构酶抗体滴度中位下降70.6%,71%和43%患者分别达到修订ACR-CRISS 25和50应答。

要点

  • teclistamab可深度清除骨髓和皮肤中的B细胞与浆细胞。
  • 抗拓扑异构酶抗体滴度中位下降70.6%,血清IgG和疫苗滴度亦下降。
  • 中位随访3.75个月,71%和43%患者分别达到ACR-CRISS 25和50应答。

核心结论

  • teclistamab诱导B细胞和浆细胞的深部组织清除,并带来快速临床和血清学应答,证据提示炎症消退和潜在纤维化过程修饰。

研究设计与样本

  • 采用免疫组化和流式细胞术分析皮肤和骨髓样本,ELISA定量血清抗体,以ACR-CRISS等评估临床疗效。

主要发现

  • 2例晚期SSc心脏受累患者在治疗开始后不久死亡。
  • 骨髓和皮肤中B细胞与浆细胞近乎完全清除,抗拓扑异构酶抗体滴度中位下降70.6%(IQR:39%),血清IgG和疫苗滴度下降。
  • 中位随访3.75个月(IQR:2.5个月),71%和43%患者分别达到修订ACR-CRISS 25和50应答。
  • 间质性肺病患者第12周观察到影像学和功能改善,用力肺活量中位增加7%(IQR:15%);改良Rodnan皮肤评分中位下降35.9%(IQR:17.9%),皮肤活检中FAP-α阳性成纤维细胞相应减少。

关键数值与推荐

  • ACR-CRISS 25应答率71%,ACR-CRISS 50应答率43%。
  • 抗拓扑异构酶抗体滴度中位下降70.6%(IQR:39%)。
  • 用力肺活量中位增加7%(IQR:15%);改良Rodnan皮肤评分中位下降35.9%(IQR:17.9%)。

临床怎么用

  • teclistamab可能作为严重难治性SSc的候选超说明书治疗,但需警惕晚期心脏受累患者早期死亡风险。
  • 治疗期间应监测B细胞和浆细胞清除、血清IgG及疫苗滴度下降带来的免疫抑制风险。

局限性

  • 2例晚期SSc心脏受累患者治疗后早期死亡,提示该人群风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate clinical outcomes, serologic changes, and immunologic effects induced by the bispecific B cell Maturation Antigen (BCMA)x Cluster of Differentiation (CD)3 T-cell-engaging antibody teclistamab in systemic sclerosis (SSc). METHODS: Patients with severe and treatment-refractory SSc were treated with teclistamab as off-label therapy. Blood and tissue samples from skin and bone marrow were analysed with immunohistochemistry and flow cytometry, serum antibodies were quantified by enzyme-linked immunosorbent assay (ELISA). Clinical efficacy was assessed using the American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) responses, among others. RESULTS: Ten patients with SSc (70% female; median age 51 years [IQR: 7]) completed 1 cycle of teclistamab. Two patients with advanced SSc heart involvement died shortly after treatment initiation. B-cells and plasma cells were almost completely eliminated from bone marrow and skin, accompanied by a median reduction of 70.6% (IQR: 39%) in antitopoisomerase antibody titres, decreases in serum IgG, and vaccination titres. After a median follow-up of 3.75 months (IQR: 2.5 months), 71% and 43% of patients achieved revised ACR-CRISS 25 and 50 responses, respectively. Among patients with interstitial lung disease, radiographic and functional improvement was observed by week 12 with a median increase in forced vital capacity of 7% (IQR: 15%). Skin fibrosis similarly improved, with a median decrease in the modified Rodnan skin score of 35.9% (IQR: 17.9%), accompanied by corresponding reductions in fibroblast activation protein (FAP)-alpha-positive fibroblasts in skin biopsy specimens. CONCLUSIONS: Teclistamab induced deep tissue depletion of B-cells and plasma cells and rapid clinical and serological responses, with evidence for resolution of inflammation and potential modification of fibrotic processes. These data suggest the potential of BCMA-directed therapies to promote immune modulation and tissue remodelling.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Siegert E, Phithak E, Albach FN, et al. Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series. Ann Rheum Dis. 2026. PMID: 42315474. doi:10.1016/j.ard.2026.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。